“Compound 19” is a JAK1/TYK2 dual kinase inhibitor from Pfizer, related to its clinical JAK1/TYK2 dual inhibitor, brepocitinib, in Ph. II for a variety of inflammatory diseases. The cyclopropyl amide…
Drug Hunter > Molecules > “Compound 19”
become a member to continue reading
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.
- Stay up-to-date and save more time with exclusive members-only content
- On-board new team members with educational content and case studies
- Generate ideas and discussion with easy-to-read slide decks
- Generate ideas and discussion with easy-to-read slide decks